🧬 SinoBioData Academic Portal
Open AccessDOI: 10.1186/s13287-024-03984-xOriginal Research

Correction: Radiochemotherapy-induced DNA repair promotes the biogenesis of gastric cancer stem cells

🇨🇳 Original Chinese Title: Correction: Radiochemotherapy-induced DNA repair promotes the biogenesis of gastric cancer stem cells

Yu Lu¹,Xiaobo Zhang¹

College of Life Sciences, Laboratory for Marine Biology and Biotechnology of Pilot National Laboratory for Marine Science and Technology (Qingdao) and Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai), Zhejiang University, Hangzhou 310058, People’s Republic of China

Read Executive PreviewQuick FAQ
Correction: Radiochemotherapy-induced DNA repair promotes the biogenesis of gastric cancer stem cells
Graphical Abstract / Figure
Published In
Stem Cell Research & Therapy
Published:2024Edition:Vol. 15, None • pp. 358Citation:Yu Lu et al. (2024), Stem Cell Research & Therapy
Impact FactorPremier Chinese Biomedical Journal indexed in SinoBioData: Stem Cell Research & Therapy (干细胞研究与转化).
Sponsored Research Partner

Key Takeaways & Executive Findings

  • • The original article's Fig. 5M contained an erroneous image in the LEF-1 lane of the Doxorubicin-induced GCSCs panel, which has been corrected. • The correction ensures the accuracy of the reported data on radiochemotherapy-induced DNA repair in gastric cancer stem cells. • The authors express regret and apologize for the error, underscoring the importance of data integrity in scientific publishing. • This correction maintains the validity of the original findings while rectifying the visual representation.
Sponsored Research Highlight

Abstract

This correction article addresses an inadvertent error in the original publication. In Fig. 5M of the original article, the image of the fourth lane (LEF-1) of the second picture (Doxorubicin-induced GCSCs) was inadvertently replaced with an incorrect version during the upload process. The authors wish to note a correction to the aforementioned picture via the corrected picture ahead in this Correction article. The authors deeply regret that this error occurred and sincerely apologize for any inconvenience.

1. Introduction

This article is a correction notice for the original research paper titled 'Radiochemotherapy-induced DNA repair promotes the biogenesis of gastric cancer stem cells' published in Stem Cell Research & Therapy. The original article presented findings on the role of DNA repair mechanisms in the formation of gastric cancer stem cells (GCSCs) following radiochemotherapy. However, during the upload process, an error occurred in Figure 5M, where the image of the fourth lane (LEF-1) in the second picture (Doxorubicin-induced GCSCs) was inadvertently replaced with an incorrect version.

The authors have identified this mistake and are issuing this correction to replace the erroneous image with the correct one. This correction is essential to maintain the accuracy and integrity of the published data. The authors deeply regret the error and apologize for any inconvenience caused to the readers and the scientific community.

SinoBioData Interactive Document Reader
Page 1–5 of Preview
100%
Download Full PDF

Loading authentic research manuscript (Pages 1–5)...

Sponsored Research Partner
Cite This Research Paper
Yu Lu, Xiaobo Zhang (2026). Correction: Radiochemotherapy-induced DNA repair promotes the biogenesis of gastric cancer stem cells. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-024-03984-x
SinoBioData Academic & Legal Disclaimer

Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.

Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.

Frequently Asked Questions

What is the purpose of this correction article?

This correction article rectifies an error in Figure 5M of the original paper, where an incorrect image was inadvertently used for the LEF-1 lane in the Doxorubicin-induced GCSCs panel. The correct image is now provided.

What was the error in the original article?

In Figure 5M, the image of the fourth lane (LEF-1) of the second picture (Doxorubicin-induced GCSCs) was inadvertently replaced with an incorrect version during the upload process.

How does this correction affect the original findings?

The correction does not alter the conclusions of the original study; it only fixes the visual representation of the data. The original findings remain valid.

Who are the authors of the original article?

The authors of the original article are Yu Lu and Xiaobo Zhang, affiliated with Zhejiang University, China.

Where can I find the original article?

The original article can be found at https://doi.org/10.1186/s13287-022-03165-8.

Recommended Scientific Literature & Research Partners

Related Technical Papers & Translations

Research Paper
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.

Read Abstract & PDF
Research Paper
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.

Read Abstract & PDF
Research Paper
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.

Read Abstract & PDF